In today’s briefing:
- HDFC/HDFC Bank Mega Merger: Foreign Selling Leads to Higher Foreign Room
- Bharat FIH Pre-IPO – The Negatives – Not a Whole Lot to Show Yet
- Piramal Enterprises (PIEL IN): Demerger to Create a Differentiated and Niche Pharmaceutical Business
- Innova Captab Pre-IPO Tearsheet
- Morning Views Asia: Vedanta Resources, Yankuang Energy Group
HDFC/HDFC Bank Mega Merger: Foreign Selling Leads to Higher Foreign Room
- Foreign selling has continued on HDFC Limited (HDFC IN) and HDFC Bank (HDFCB IN) and foreign room on the proforma merged entity is 17.23%.
- Higher than 15% foreign room will require passive MSCI trackers to buy 209m shares (US$4.05bn) of HDFC Bank (HDFCB IN) at the time of merger implementation.
- If foreign selling continues and foreign room on the merged entity exceeds 20%, there will be buying from passive FTSE trackers as well.
Bharat FIH Pre-IPO – The Negatives – Not a Whole Lot to Show Yet
- Bharat FIH (BFIH) aims to raise around US$660m in its India IPO via selling a mix of both primary and secondary shares. BFIH is a subsidiary of Foxconn.
- Its initial operations were focused on mobile phones, of late it has been expanding its portfolio to include mechanics, electric vehicles, televisions and hearables.
- In this note, we will talk about the not so positive aspects of the deal.
Piramal Enterprises (PIEL IN): Demerger to Create a Differentiated and Niche Pharmaceutical Business
- Piramal Enterprises (PIEL IN) obtained shareholders nod for demerging its pharma business and consolidated under Piramal Pharma Limited (PPL). Later, PPL will be listed on India stock exchange.
- PPL has a differentiated pharmaceutical business model, with three business verticals. CDMO, the largest revenue contributor, has track record of consistent above-market growth due to its niche and complex capabilities.
- Listed as a separate entity, PPL will see multiple expansion and command premium valuation over other Indian generic drug makers, due to its niche and limited competition portfolio.
Innova Captab Pre-IPO Tearsheet
- Innova Captab (1605221D IN) is looking to raise about US$115m in its upcoming India IPO. The deal will be run by ICICI and JM Financial.
- Innova Captab is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports.
- Its business includes a contract development and manufacturing organization (CDMO) business providing manufacturing services to Indian pharmaceutical companies, a domestic branded generics business and an international branded generics business.
Morning Views Asia: Vedanta Resources, Yankuang Energy Group
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars